KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 13 years, with Q4 2025 value amounting to $59.5 million.

  • Alnylam Pharmaceuticals' Other Non-Current Assets fell 895.57% to $59.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $59.5 million, marking a year-over-year decrease of 895.57%. This contributed to the annual value of $59.5 million for FY2025, which is 895.57% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Other Non-Current Assets of $59.5 million as of Q4 2025, which was down 895.57% from $55.8 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Other Non-Current Assets ranged from a high of $92.7 million in Q2 2023 and a low of $34.6 million during Q2 2021
  • For the 5-year period, Alnylam Pharmaceuticals' Other Non-Current Assets averaged around $63.5 million, with its median value being $64.4 million (2023).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Other Non-Current Assets surged by 12423.29% in 2021, and later plummeted by 2806.44% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Other Non-Current Assets stood at $60.2 million in 2021, then increased by 9.78% to $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then grew by 5.51% to $65.3 million in 2024, then fell by 8.96% to $59.5 million in 2025.
  • Its Other Non-Current Assets was $59.5 million in Q4 2025, compared to $55.8 million in Q3 2025 and $57.2 million in Q2 2025.